Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

2488 - Impact of primary tumour resection on survival and chemotherapy tolerance in patients with metastatic oesophagogastric cancer undergoing palliative chemotherapy


08 Oct 2016


Poster Display


Sebastian Ochenduszko


Annals of Oncology (2016) 27 (6): 207-242. 10.1093/annonc/mdw371


S. Ochenduszko1, M. Puskulluoglu2, K. Konopka1, A. Michalowska-Kaczmarczyk1, K. Fijorek3, M. Pedziwiatr4, A. Budzynski4

Author affiliations

  • 1 Department Of Oncology, University Hospital in Krakow, 31-531 - Krakow/PL
  • 2 Department Of Oncology, Jagiellonian University Medical College, 31-531 - Krakow/PL
  • 3 Department Of Statistics, Krakow University of Economics, Krakow/PL
  • 4 2nd Department Of General Surgery, Jagiellonian University Medical College, 31-501 - Krakow/PL


Abstract 2488


The role of primary tumour resection in patients with metastatic oesophagogastric adenocarcinoma (mOGA) undergoing palliative chemotherapy (CTH) is the subject of an intense debate. We decided to analyse retrospectively the impact of primary tumour resection on survival and CTH tolerance in patients with mOGA undergoing palliative CTH.


Patients with mOGA who started palliative CTH between January 2010 and May 2015 were identified from the electronic database of the Department of Oncology at the University Hospital in Krakow. We performed a charts review to obtain baseline demographics, performance status, laboratory parameters, dates of progression, death and last follow-up. Patients were divided into two groups: A-primary tumour resected, B-primary tumour present. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan–Meier method.


One hundred sixty-five patients were identified: group A n = 89, group B n = 76. No significant differences in baseline characteristics were observed. Median OS was 10.5 months (95% CI 8.5-13.5) in group A vs 8.4 months (6.0-10.5) in group B (log-rank p = 0.013). Median PFS was 6.4 months (4.8-7.5) and 5.1 months (4.1-6), respectively (log-rank p = 0.019). There were no statistically significant differences in grade 3 or 4 chemotherapy-related adverse events between groups: anaemia (gr. A 5.8% vs gr. B 9.7%), leukopenia (11.6% vs 15.3%), neutropenia (47.7% vs 43.1%), febrile neutropenia (4.7% vs 5.6%), thrombocytopenia (1.2% vs 0.0%), nausea (1.2% vs 1.4%), vomiting (2.3% vs 1.4%), diarrhoea (5.8% vs 1.4%), anorexia (3.5% vs 4.2%), fatigue (3.5% vs 4.2%), mucositis (1.2% vs 1.4%), hand-foot syndrome (1.2% vs 0.0%), peripheral neuropathy (1.2% vs 0.0%). No statistically significant differences were observed for CTH cycle delays (gr. A 71.6% vs gr. B 68.5%; p = 0.799) and CTH dose reductions (gr. A 28.4% vs gr. B 20.3%; p = 0.311).


In this retrospective analysis, primary tumour resection in patients with mOGA improved OS and did not influence the tolerance of palliative CTH. Updated data with a longer follow-up will be presented.

Clinical trial identification

Legal entity responsible for the study

Jagiellonian University Medical College, Krakow, Poland


Jagiellonian University Medical College, Krakow, Poland


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings